Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Adamis Pharmaceuticals Corp. (NASDAQ: ADMP).

Full DD Report for ADMP

You must become a subscriber to view this report.

Recent News from (NASDAQ: ADMP)

ADMP And Sandoz Announce Plans For SYMJEPI Launch
Sources Investors finally received updates from Adamis ( ADMP ) and Sandoz about the planned launch of SYMJEPI. The Adamis press release was short, but provided some insight on the company’s recent actions to support the launch. According to the press release, “Manufact...
Source: SeekingAlpha
Date: December, 07 2018 13:24
FDA to hold Ad Com meeting aimed at increasing access to opioid overdose med naloxone
The FDA announces a two-day advisory committee, to be held in December, to solicit input and advice on ways to increase access to opioid overdose medication naloxone. More news on: Emergent BioSolutions Inc., Adamis Pharmaceuticals Corp., Opiant Pharmaceuticals, Inc., Healthcare stocks n...
Source: SeekingAlpha
Date: October, 23 2018 13:07
Report: Developing Opportunities within Adamis Pharmaceuticals, Cass Information, Celldex Therapeutics, Par Pacific, Inovio Pharmaceuticals, and Liberty Global - Future Expectations, Projections Moving into 2018
NEW YORK, Oct. 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), Cass Information System...
Source: GlobeNewswire
Date: October, 09 2018 07:50
Adamis And Novartis: Gunning For Mylan's EpiPen
Product Pipeline Adamis' ( ADMP ) lead product is the Symjepi pre-filled syringe injector that contains epinephrine for its use in the treatment of acute allergic reactions, including anaphylaxis, a serious life-threatening allergic reaction. Adamis offers a high dose 0.30mg variant for pa...
Source: SeekingAlpha
Date: October, 04 2018 07:30
Adamis Pharmaceuticals: Where Do We Go From Here?
For investors in Adamis Pharmaceuticals (ADMP), the wait is finally over. On Thursday, Adamis obtained approval for its low-dose Epinephrine medication, Symjepi. The company previously had approval for the 0.30mg version of Symjepi, and the FDA approval of Symjepi for a 0.15mg dose for pedia...
Source: SeekingAlpha
Date: October, 01 2018 00:01
Midday Gainers / Losers (09/28/2018)
Gainers: SYN +207% . IGC +36% . NBEV +31% . AYTU +23% . ZN +21% . CCXI +17% . IMMP +14% . SPNS +14% . PRSS +13% . AC +12% . More news on: Synthetic Biologics, Inc., India Globalization Capital, Inc, New Age Beverages Corporation, Stocks on the move, , Top s...
Source: SeekingAlpha
Date: September, 28 2018 12:40
FDA OKs Adamis Pharma's low-dose Symjepi
The FDA approves Adamis Pharmaceuticals' (NASDAQ: ADMP ) lower-dose version (0.15 mg) of emergency allergic reaction med Symjepi (epinephrine) for pediatric use. More news on: Adamis Pharmaceuticals Corp., Novartis AG, Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: September, 27 2018 16:18
Adamis Pharmaceuticals Receives FDA Approval for Its Lower Dose Symjepi Product
SAN DIEGO, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved Adamis’ lower dose version (0.15mg) of Symjepi ™ for the ...
Source: GlobeNewswire
Date: September, 27 2018 16:05
Adamis Pharmaceuticals, FDA PDUFA Action Anticipated, Analyst Coverage
NEW YORK, NY / ACCESSWIRE / September 26, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) , a specialty biopharm...
Date: September, 26 2018 08:15
Catalyst Watch: Adamis Faces A Big FDA Decision This Week On Symjepi Jr.
Adamis Pharmaceuticals ( ADMP ) faces its next big FDA hurdle this week. September 27 th is the PDUFA deadline for Symjepi Jr., the low dose variant of the company’s Symjepi product, a prefilled syringe injector for delivering epinephrine to patients. All approval decisions carry ris...
Source: SeekingAlpha
Date: September, 25 2018 12:37


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ADMP.

About Adamis Pharmaceuticals Corp. (NASDAQ: ADMP)

Logo for Adamis Pharmaceuticals Corp. (NASDAQ: ADMP)

Adamis Pharmaceuticals Corporation is a publicly traded OTC: ADMP biopharmaceutical company combining specialty pharmaceuticals and biotechnology products to create a variety of treatment options in the areas of oncology cancer , immunology, infectious diseases viruses , as well as allergic and respiratory conditions. Adamis is built on a business model that entails licensing innovative programs from companies or institutions and then advancing these initiatives through clinical development, regulatory approvals, and marketing. In order to efficiently accomplish its objectives, the Company operates through two subsidiaries Adamis Laboratories specialty pharmaceuticals and Adamis Therapeutics biotechnology . This structure permits each division to complement one other by providing a combination of pharmaceutical revenue and biotechnology blockbuster potential. The specialty pharmaceutical division will provide revenue to support the development of the Company s therapeutic products.


Contact Information



Current Management

  • Dennis J. Carlo / President, CEO
  • Robert O. Hopkins / CFO
  • David J. Marguglio / SVP, Corp. Dev.
  • Dennis J. Carlo /
  • Kenneth M. Cohen /
  • Craig Johnson /
  • David J. Marguglio /
  • Tina S. Nova /

Current Share Structure

  • Market Cap: $126,879,758 - 05/14/2018
  • Issue and Outstanding: 33,389,410 - 03/15/2018


Recent Filings from (NASDAQ: ADMP)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 11 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: April, 30 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 27 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: February, 14 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: February, 14 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: February, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 05 2018



Daily Technical Chart for (NASDAQ: ADMP)

Daily Technical Chart for (NASDAQ: ADMP)

Stay tuned for daily updates and more on (NASDAQ: ADMP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ADMP)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ADMP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ADMP and does not buy, sell, or trade any shares of ADMP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: